News & Events about Portage Biotech Inc.
Globe Newswire
3 months ago
Updated data support the proof of concept of using an iNKT agonist monotherapy (PORT-2) to induce immune response for patients with refractory NSCLC and melanomaWESTPORT, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing...
Globe Newswire
3 months ago
Study will evaluate PORT-2 in combination with KEYTRUDA (pembrolizumab) for the treatment of patients with front-line as well as refractory non-small cell lung cancer (NSCLC)WESTPORT, Conn., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (Portage or the Company), a clinical-...
Globe Newswire
5 months ago
--Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn., Aug. 29, 2022 (GLOBE NEWSWIRE...
Globe Newswire
6 months ago
--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets-- --Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn., Aug. ...
Globe Newswire
6 months ago
Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stockWESTPORT, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and ...